Skip to main content

Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer.

Publication ,  Journal Article
Glaser, A; Shi, Z; Wei, J; Lanman, NA; Ladson-Gary, S; Vickman, RE; Franco, OE; Crawford, SE; Lilly Zheng, S; Hayward, SW; Isaacs, WB; Xu, J ...
Published in: Eur Urol Open Sci
September 2022

BACKGROUND: The association between benign prostatic hyperplasia (BPH) and prostate cancer (PCa) remains controversial, largely due to a detection bias in traditional observational studies. OBJECTIVE: To assess the association between BPH and PCa using inherited single nucleotide polymorphisms (SNPs). DESIGN SETTING AND PARTICIPANTS: The participants were White men from the population-based UK Biobank (UKB). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The association between BPH and PCa was tested for (1) phenotypic correlation using chi-square, (2) genetic correlation (r g) based on genome-wide SNPs using linkage disequilibrium score regression, and (3) cross-disease genetic associations based on known risk-associated SNPs (15 for BPH and 239 for PCa), individually and cumulatively using genetic risk score (GRS). RESULTS AND LIMITATIONS: Among 214 717 White men in the UKB, 24 623 (11%) and 14 311 (6.7%) had a diagnosis of BPH and PCa, respectively. Diagnoses of these two diseases were significantly correlated (χ2 = 1862.80, p < 0.001). A significant genetic correlation was found (r g = 0.16; 95% confidence interval 0.03-0.28, p = 0.01). In addition, significant cross-disease genetic associations for established risk-associated SNPs were also found. Among the 250 established genome-wide association study-significant SNPs of PCa or BPH, 49 were significantly associated with the risk of the other disease at p < 0.05, significantly more than expected by chance (N = 12, p < 0.001; χ2 test). Furthermore, significant cross-disease GRS associations were also found; GRSBPH was significantly associated with PCa risk (odds ratio [OR] = 1.26 [1.18-1.36], p < 0.001), and GRSPCa was significantly associated with BPH risk (OR = 1.03 [1.02-1.04], p < 0.001). Moreover, GRSBPH was significantly and inversely associated with lethal PCa risk in a PCa case-case analysis (OR = 0.58 [0.41-0.81], p = 0.002). Only White men were studied. CONCLUSIONS: BPH and PCa share common inherited genetics, which suggests that the phenotypic association of these two diseases in observational studies is not entirely caused by the detection bias. PATIENT SUMMARY: For the first time, we found that benign prostatic hyperplasia and prostate cancer are genetically related. This finding may have implications in disease etiology and risk stratification.

Duke Scholars

Published In

Eur Urol Open Sci

DOI

EISSN

2666-1683

Publication Date

September 2022

Volume

43

Start / End Page

54 / 61

Location

Netherlands

Related Subject Headings

  • Urology & Nephrology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Glaser, A., Shi, Z., Wei, J., Lanman, N. A., Ladson-Gary, S., Vickman, R. E., … Xu, J. (2022). Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer. Eur Urol Open Sci, 43, 54–61. https://doi.org/10.1016/j.euros.2022.07.004
Glaser, Alexander, Zhuqing Shi, Jun Wei, Nadia A. Lanman, Skylar Ladson-Gary, Renee E. Vickman, Omar E. Franco, et al. “Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer.Eur Urol Open Sci 43 (September 2022): 54–61. https://doi.org/10.1016/j.euros.2022.07.004.
Glaser A, Shi Z, Wei J, Lanman NA, Ladson-Gary S, Vickman RE, et al. Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer. Eur Urol Open Sci. 2022 Sep;43:54–61.
Glaser, Alexander, et al. “Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer.Eur Urol Open Sci, vol. 43, Sept. 2022, pp. 54–61. Pubmed, doi:10.1016/j.euros.2022.07.004.
Glaser A, Shi Z, Wei J, Lanman NA, Ladson-Gary S, Vickman RE, Franco OE, Crawford SE, Lilly Zheng S, Hayward SW, Isaacs WB, Helfand BT, Xu J. Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer. Eur Urol Open Sci. 2022 Sep;43:54–61.

Published In

Eur Urol Open Sci

DOI

EISSN

2666-1683

Publication Date

September 2022

Volume

43

Start / End Page

54 / 61

Location

Netherlands

Related Subject Headings

  • Urology & Nephrology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences